Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Publishes BsUFA III Commitment Letter Ahead Of 2022 Renewal

Biosimilar Supplement Review Goals Aim To Speed Approvals

Sep 22 2021

• By Dean Rudge

Entrance to FDA headquarters in Maryland — BSUFA III covers the fiscal years 2023-27 • Source: Shutterstock

Related Content

BsUFA III Negotiations Nearly Done; Commitment Letter Being Written

Jun 10 2021

Viatris Wins Landmark First US Interchangeability Designation For Semglee

Jul 29 2021

First Interchangeability Designation Opens Doors For Biosimilars

Aug 17 2021

Two Months To Add Two Words – Biosimilar Supplement Review Times May Be Hindering Uptake

May 01 2019

GDUFA III Talks Completed

Sep 03 2021

Additional Topics

United States Biosimilars FDA Regulation Review Pathway User Fees BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window